Adaptive Biotechnologies Corporation Common Stock (ADPT): valor razonable

Tesis ACCE

Adaptive Biotechnologies sells immune-profiling products built on its sequencing platform, chiefly the clonoSEQ assay for tracking minimal residual disease in blood cancers and the immunoSEQ platform used by researchers and drug developers to read T-cell and B-cell receptor repertoires. The moat is the installed base of validated clinical data and reimbursement for clonoSEQ, which gives it a diagnostic franchise that rivals must clear with their own evidence before they can compete. Revenue grew 21.5% over the latest period and gross margin sits at 46.9%, so the question is whether that growth can carry operating losses, currently a 22.0% operating margin deficit, toward breakeven. The stock scores 48 out of 100 and is not in any major index, which keeps the name under-owned and worth a look only if you are prepared to underwrite the path to profitability and the continued expansion of clonoSEQ volumes. Return on equity of negative 38.8% confirms the company is still consuming capital rather than generating it.